1. Scrip
  2. >>Business
  3. >>Deals

Tech Transfer Roundup: UCSD Sees Many Benefits From Entrepreneurs In Residence Program

 
• By Joseph Haas and Jung Won Shin

Asterias obtains IP estate related to ischemic stroke from University of California. Plus Apeiron, Qualigen, Biovaxys and AbbVie turn to academic partners for early-stage cancer assets.

Tech Transfer regular column feature image

Shortly after arriving at University of California, San Diego as its director of commercialization, Ruben Dario Flores-Saaib initiated an “entrepreneurs in residence” program that in two years helped spur the creation of five start-ups around research conducted at the school.

Flores-Saaib, a 12-year biopharma industry veteran who helped establish and lead a bioscience academic alliances team at Merck KGAA/EMD Millipore for five years, told Scrip the entrepreneurs in residence (EIR) initiative has yielded benefits beyond start-up formation, including educating faculty and graduate students on the

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Biopharma Deals ROI Has Fallen And Market Instability Could Make It Worse

 
• By Andrew McConaghie

Rising biotech valuations mean return on investment on some deals is non-existent for big pharma, though certain strategies will improve chances of success, a new analysis has found.

Dr Reddy’s Gears For Tariffs Scenario To Ensure No US Supply Disruption

 
• By Anju Ghangurde

Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: industry makes its case to Trump; Sarepta slammed by double blow; Chinese firms build obesity pipeline; Swiss biopharma staying strong; and Merck & Co looks to immunology and ophthalmology.